Scott L. Burrows, Chief Financial Officer at Spyre Therapeutics, Inc. (SYRE), sold 2,500 shares at $41.66 ($102K) on 2026-03-03, disclosed to the SEC on 2026-03-03.
Scheduled sale ($102k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $40.56 | 2,300 | $93K | 91.8% |
| 2 | $41.66 | 200 | $8K | 8.2% |
| Total | $40.65 avg | 2,500 | $102K | 100% |
| Filing → |
| SYRE | SELL | 2026-08-05 | $717K | — | Filing → |
| SYRE | SELL | 2026-07-02 | $658K | — | Filing → |
| SYRE | SELL | 2026-06-26 | $1.3M | — | Filing → |